Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

Bristol-Myers Squibb Company (NYSE:BMY) slid more than 2% in premarket trading Thursday after the company's guidance for 2025 missed average analyst expectations.

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...

Worse, rival Bristol-Myers Squibb (NYSE:BMY) had previously been approved for its own schizophrenia treatment. More than 24 million patients globally made the drug a significant growth opportunity.

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly immunotherapy, but it is burdened by a lot of debt. Although the dividend yield ...

PRINCETON, N.J., January 31, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Breyanzi--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the ...

He called on the CEOs of some of the largest pharmaceutical companies, including Merck, Bristol Myers Squibb and Johnson & Johnson to testify at the hearing. An in 2019, Sen Sanders, along with ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Bristol Myers Squibb (BMY) reports results for the quarter ended December 2024. While this widely-known consensus ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best blue chip stocks to buy under $100. Blue chip stocks have long been ...

Logan went the distance in a fight against pound-for-pound great, Floyd Mayweather, while Jake Paul has fought against multiple former UFC fighters including Nate Diaz and Tyron Woodley.